Circulating microRNA-197-3p as a potential biomarker for asbestos exposure

Francesca Frontini,^{1†} Ilaria Bononi,^{2†} Elena Torreggiani,¹ Giulia Di Mauro,¹ Elisa Mazzoni,¹ Mariarita Stendardo,³ Piera Boschetto,³ Roberta Libener,⁴ Roberto Guaschino,⁵ Federica Grosso,⁶ Giovanni Guerra,^{7,8} Fernanda Martini,^{1*} and Mauro Tognon^{1*}

¹ Laboratories of Cell Biology and Molecular Genetics, Section of Experimental Medicine, Department of Medical Sciences, School of Medicine, University of Ferrara, 44121 Ferrara, Italy;

² Department of Translational Medicine and for Romagna, University of Ferrara, 44121 Ferrara, Italy;

³ Department of Medical Sciences, Unit of Occupational Medicine, University of Ferrara, 44121 Ferrara, Italy;

⁴ Department of Integrated Activities Research and Innovation - SS. Antonio and Biagio and Cesare Arrigo Hospital, 15121 Alessandria, Italy;

⁵ Blood Transfusion Centre, City Hospital, 15121 Alessandria, Italy;

⁶ Mesothelioma Unit - SS. Antonio and Biagio and Cesare Arrigo Hospital, 15121 Alessandria, Italy;

⁷ Clinical Laboratory Analysis, University Hospital of Ferrara, 44121 Ferrara, Italy;

⁸ Present address: Clinical Laboratory Analysis, City Hospital of Bergamo, 21127 Bergamo, Italy

* **Correspondence to:** Prof. Mauro Tognon Laboratories of Cell Biology and Molecular Genetics, Section of Experimental Medicine, Department of Medical Sciences, School of Medicine, University of Ferrara, 44121 Ferrara, Italy; tgm@unife.it, Tel. +39-0532-455538;

or Prof. Fernanda Martini Laboratories of Cell Biology and Molecular Genetics, Section of Experimental Medicine, Department of Medical Sciences, School of Medicine, University of Ferrara, 44121 Ferrara, Italy; mrf@unife.it, Tel. +39 0532 455540

† These authors contributed equally

Abstract

Asbestos is considered the main cause of diseases in workers exposed to this mineral in the workplace as well as an environmental pollutant. The association between asbestos and the onset of different diseases has been reported, but asbestos exposure specific biomarkers are not known. MicroRNAs (miRNAs) are small, single-strand, non-coding RNAs, with potential value as diagnostic, prognostic, and predictive markers in liquid biopsies. Sera collected from workers ex-exposed to asbestos (WEA) fibers were compared with sera from healthy subjects (HS) of similar age, as liquid biopsies. The expression of the circulating miRNA 197-3p was investigated employing two different highly analytical PCR methods, i.e. RT-PCR and dd-PCR. MiR-197-3p levels were tested in sera from WEA compared to HS. MiR-197-3p tested dysregulated in sera from WEA (n=75) compared to HS (n=62). Indeed, miR-197-3p was found to be 2.6 times down-regulated in WEA vs. HS ($p=0.0001^{***}$). In addition, an inverse correlation was detected between miR-197-3p expression level and cumulative asbestos exposure, being this miRNA down-regulated 2.1 times in WEA, with high cumulative asbestos exposure, compared to WEA with low exposure ($p=0.0303^{*}$). Circulating miR-197-3p, found to be down regulated in sera from WEA, is proposed as a new potential biomarker of asbestos exposure.

Keywords: asbestos; worker; serum; microRNA; biomarker; ddPCR

INTRODUCTION

Asbestos is a natural mineral ¹ of known oncogenic properties. Asbestos fibers are found in nature with different chemical compositions and physical forms ¹

Since it is considered indestructible, this natural mineral has been used and distributed worldwide. Asbestos has been employed mainly in heat resistant artifacts. Due to its insulation characteristic, it has been used extensively in shipyards and construction. Exposure in the workplace has been significant for asbestos miners and millers, as well as for those exposed during secondary manufacturing uses. These workers were historically subject to very heavy inhalation exposure, as a result of mixing and spraying asbestos on the job ². Although asbestos has been banned in many countries, it should be recalled that in some areas, mainly in the developing world, its use remains unregulated ³.

Inhaled asbestos fibers cause serious pathologies of the respiratory system, such as asbestosis, interstitial fibrosis, malignant lung and laryngeal cancers, malignant pleural mesothelioma (MPM), and neoplasms of other organs, i.e., peritoneal, pericardial, and testicular vaginal tunic mesothelioma, as well as malignant tumors of the ovary ⁴. Asbestos related diseases arise mainly in workers exposed to the mineral in the workplace ⁵. Asbestos fibers trapped between the pleural layers and the wall of the chest cavity induce oxidative stress and chronic inflammation, thus promoting a potential disease/carcinogenesis process ⁶. It has been reported that asbestos is cytotoxic, clastogenic and mutagenic, whereas in human cells it induces specific structural and numerical chromosomal aberrations, as well as oncogene and tumor suppressor gene mutations, including K-RAS and p53, respectively ⁷. Of all asbestos-related diseases, malignant pleural mesothelioma (MPM) onset may occur in workers ex-exposed to asbestos (WEA), even decades after inhalation of the fibers of this natural tumorigenic mineral ⁸.

In this context, it should be recalled that asbestos has become an environmental pollutant, too, affecting subjects/patients who previously were not open to exposure in the workplace ⁹. The

association between asbestos exposure and the onset of different diseases has been reported by many investigators ¹⁰.

Several publications based on toxicological investigations have pointed to the risk of respiratory disease onset being associated with fiber dimensions. Phase contrast microscopy (PCM) and transmission electron microscopy (TEM) analyses carried out in relation to fiber dimensions have indicated that this asbestos parameter is significant in assessing the risk of respiratory disease onset among WEA cohorts ¹¹. Such risks, including MPM, were also investigated in subjects who had been exposed to asbestos fibers in non-occupational environments, such as in the household and residential areas ⁹. These investigations indicate that the risk of MPM onset from non-occupational asbestos exposure is related to the fiber-type. To date, no known factor can predict disease onset/evolution with certainty.

Liquid biopsies represent promising samples for analysis in identifying asbestos exposure markers. Indeed, until now no single biomarker has yet been reported. Indeed, the identification of specific, sensitive biomarkers, providing early, effective diagnosis in high-risk subjects is of paramount interest.

MicroRNAs (miRNAs) are small, single-strand, non-coding RNAs, with potential value as diagnostic, prognostic, predictive markers for different diseases. Many studies have indicated that miRNA expression is altered in cells and body fluids from patients affected by different diseases, while miRNAs detected in biological samples are stable and quantifiable. These data suggest that miRNAs isolated from liquid biopsies, such as serum/blood samples, can be employed as promising disease biomarkers, which include different pathologies springing from asbestos exposure ^{12,13}. To date, specific biomarkers of asbestos exposure have been poorly investigated.

In a previous comparative study, carried out on sera with a small-sized sample from MPM, WEA and HS cohorts, three miRNAs, i.e., miR-197-3p, miR-1281 and miR 32-3p, were found to be dysregulated using two relative techniques, such as microarray and RT-qPCR ¹⁴. Herein, in order to undertake a significant statistical analysis, a new larger-sized sample of sera was investigated with

novel absolute quantitative techniques. MiR-197-3p appears as the most promising microRNA to be analyzed. Indeed, preliminary data indicated that miR 197-3p was the only miR out of three found to be expressed in all sera analyzed.

In this investigation, sera collected from workers who had previously been exposed to asbestos (WEA) fibers were employed in our study, alongside sera from healthy subjects (HS), as liquid biopsies. In order to find a specific miRNA to be used as a biomarker for asbestos exposure sera were analyzed by quantitative PCR (qPCR) methods, such as Real-Time qPCR (RT-qPCR) and droplet digital PCR (ddPCR) techniques. It should be recalled that droplet digital PCR (ddPCR) is an improvement on conventional PCR technique, as it allows a more sensitive, accurate, absolute quantification of target nucleic acids, even when present in low target copies. MiR-197-3p was analyzed in this study using both qPCR techniques on differing circulating miRNAs from a large sample size of sera, which included WEA (n=75) and HS (n=62).

METHODS

Serum samples

Serum samples from WEA (n=75) were collected by two reference centers of the post-occupational medical surveillance program for asbestos workers, supported by the Italian Ministry of Health (i) the "Workplace prevention, hygiene and safety service", of Dolo and (ii) the Occupational Medicine Unit, University of Ferrara, Italy. WEA participated on a voluntary basis and excluded if affected by MPM. Sera from HS (n=62) were collected at the Clinical Laboratory Analysis of the University Hospital of Ferrara, Italy, from individuals who were admitted for a routine check-up. Both cohorts' subjects are of similar age (WEA 66.3+6.6 and HS 65.3+17.0 years + SD). All subjects signed an informed consent and the County Ethical Committee, Ferrara, Italy, approved the project (n. 151078). All sera were obtained with the same procedure and coded anonymously with indications of age and gender. Clinicopathological characteristics, occupational and non-occupational information, were collected from the WEA cohort (Tables 1 and 2).

Table 1. Exposition data of the WEA cohort. * p<0.05 compared to Range 3. † Data available for 64 out of 75 (85.3%) subjects. ‡ Data available for 60 out of 75 (80%) subjects. § Data available for 62 out of 75 (82.7%) subjects.

Exposition characteristics (unit of measure)	Range or Diagnosis	N (%)
Cumulative asbestos exposure fibers (Asbestos fibers/cm ³ of air, ff/cc)	Range 1: 0-8	21 (28.0) *
	Range 2: 8.1-55	21 (28.0) *
	Range 3: >55	22 (29.3)
	N/A	11 (14.7) †
Asbestos exposure (Years)	Range 1: 0-20	14 (18.7)
	Range 2: 21-30	24 (32.0)
	Range 3: >30	26 (34.7)
	N/A	11 (14.7) †
Time since last previous asbestos exposure (Years)	Range 1: 0-10	14 (18.7)
	Range 2: 11-20	25 (33.3)
	Range 3: 21-30	17 (22.7)
	Range 4: >30	8 (10.7)
	N/A	11 (14.7) †
Tobacco smoking status (Smoker/Ex/Non)	Smoker	11 (14.7)
	Ex-smoker	30 (40.0)
	Non-smoker	19 (25.3)
	N/A	15 (20.0) ‡

Tobacco smoking amount (Pack/Year, P/Y)	Range 1: 0	23 (30.7)
	Range 2: 0.1-10	16 (21.3)
	Range 3: 10.1-20	13 (17.3)
	Range 4: >20	12 (16.0)
	N/A	11 (14.7) [†]
Asbestosis or other asbestos related pathologies (Pathologies)	Pleural thickening	2 (2.7)
	Pleural plaques	3 (4.0)
	Fibrosis	1 (1.3)
	Bronchiectasis	1 (1.3)
	Emphysema	1 (1.3)
	Not related to asbestos	54 (72.0)
	N/A	13 (17.3) [§]

Table 2. Clinicopathological characteristics of the WEA cohort. * Data available for 64 out of 75 (85.3%) subjects.

Diseases, not related to asbestos	Yes/No	N (%)
Musculoskeletal diseases (Yes/No)	Yes	7 (9.3)
	No	57 (76.0)
	N/A	11 (14.7) [*]
Cardiovascular diseases (Yes/No)	Yes	29 (38.7)
	No	35 (46.7)
	N/A	11 (14.7) [*]
Gastrointestinal diseases (Yes/No)	Yes	10 (13.3)
	No	54 (72.0)
	N/A	11 (14.7) [*]
Endocrine diseases (Yes/No)	Yes	20 (26.7)
	No	44 (58.7)
	N/A	11 (14.7) [*]
Respiratory diseases (Yes/No)	Yes	15 (20.0)
	No	49 (65.3)
	N/A	11 (14.7) [*]
Neurological diseases (Yes/No)	Yes	5 (6.7)
	No	59 (78.7)
	N/A	11 (14.7) [*]
Genitourinary diseases (Yes/No)	Yes	11 (14.7)
	No	53 (70.7)
	N/A	11 (14.7) [*]
Neoplastic diseases (Yes/No)	Yes	10 (13.3)
	No	54 (72.0)
	N/A	11 (14.7) [*]
Therapy (Yes/No)	Yes	57 (76.0)
	No	18 (24.0)
	N/A	(0.0)

RNA extraction and retro-transcription (RT)

Total RNA, including miRNAs, was extracted from 200 µl of serum using the miRNeasy Mini Kit (Qiagen Cod. 217004) according to the manufacturer's protocol. RNA was eluted in 30 µl RNase-free water and retro-transcribed using the miRCURY LNA RT kit (Qiagen Cod. 339340) following the manufacturer's protocol. RT products were stored at -20°C until time of qPCR analyses. Before amplification, cDNA was diluted 1:60 to avoid interference between the two enzyme mixes ¹⁴.

MiRNA quantification, calibration and control

Hsa-miR-197-3p concentrations were analyzed by qPCR techniques using the specific miRCURY LNA miRNA PCR Assay (Qiagen Cod. 339306). Standard curves were generated through 1:10 serial dilutions for hsa-miR-197-3p, using Specific synthetic Locked Nucleic Acid (LNA) oligonucleotides (Qiagen Cod. 339306, ID: YP00204380). Stock solutions (100 µM) of synthetic oligonucleotides were prepared according to the manufacturer's protocol. These standards were used for absolute quantification of miRNAs by RT-qPCR ¹⁵, and as positive controls in ddPCR.

Analysis of miRNA by PCR techniques

RT-qPCR reactions were performed using the miRCURY LNA SYBR Green PCR Kit (Qiagen Cod. 339346) according to the manufacturer's instructions. Standard curves were run in parallel with samples to perform an absolute quantification of miR-197-3p.

LNA-based miRNA-specific primers were used in ddPCR with the QX200ddPCR System (Bio-Rad). A no template control (NTC), a negative control for each reverse transcription reaction (RT-neg) and a positive control were included for each PCR assay.

QuantaSoft software was used to determine specific intensity thresholds for the assay and results were exported to a spreadsheet for further analysis.

Statistical analysis

Statistical analyses were performed using Prism 8.0 statistical software (GraphPad software, La Jolla, CA, USA). Data were analyzed using ANOVA, t-test, with or without Welch's correction, and Chi-square¹⁶. If distribution was abnormal, the Kruskal–Wallis test and Mann–Whitney test, were employed. Receiver Operating Characteristic (ROC) analysis was used to assess the accuracy of RT-qPCR and ddPCR results. Moreover, linear regression model and multiple regression analysis were performed. P value <0.05 was considered as statistically significant.

RESULTS

MicroRNA analysis

In a previous study, carried out with a small sample size of sera¹⁴ three miRNAs, i.e., miR-197-3p, miR-1281 and miR 32-3p, were found to be dysregulated. In the present study, in order to reach statistically significant data, a large-sized sample of sera was investigated employing novel absolute quantitative methods, such as RT-qPCR and ddPCR techniques. Herein, miR-197-3p was investigated since it appears to be a promising circulating biomarker. Indeed, preliminary data indicated that miR-197-3p, out of the three dysregulated miRs, was found as expressed in all analyzed samples, which included WEA (n=75) and HS (n=62) (see below). In the first step of our study, RT-qPCR detected miR-197-3p in all analyzed sera (n=137). A significantly different quantification of miR-197-3p was revealed in the two cohorts, i.e., WEA and HS (ANOVA: $p=0.0009^{***}$). Specifically, a mean of 336.0 copies of miR-197-3p/ul was detected in the WEA cohort. This quantity is significantly lower than in the HS group (870.1 copies/ul cDNA, t-test: $p=0.0001^{***}$). Hence, miR-197-3p was found to be down-regulated 2.6 times in WEA vs. HS (Fig. 1a). Receiver Operating Characteristic (ROC) analysis was used to quantify the accuracy of RT-qPCR results in discriminating data in significant comparisons. The ROC AUC for the comparative analysis of miR-197-3p levels in WEA vs. HS was 0.727 ($p < 0.0001^{***}$; 95% confidence interval 0.641 to 0.813) (Fig. 1b). These ROC analyses indicate that miR-197-3p levels significantly discriminate WEA from HS. Subsequently, miR-197-3p was analyzed in the same sera (n=137) using ddPCR. MiR-197-3p was detectable in all analyzed samples (n=137). DdPCR analysis showed significant miR-197-3p dysregulation in the WEA cohort compared to HS (ANOVA: $p=0.0004^{***}$). A mean of 525.0 copies of miR-197-3p/μl was detected in WEA. Its serum level was significantly lower than HS (1316 copies/μl cDNA, t-test: $p < 0.0001^{****}$). Hence, miR-197-3p was down-regulated 2.5 times in WEA vs. HS (Fig. 1c). ROC analysis was used to quantify the accuracy of ddPCR results in discriminating

data in significant comparisons. The ROC AUC for miR-197-3p in the comparison between WEA vs. HS was 0.755 ($p < 0.0001^{***}$; 95% confidence interval 0.675 to 0.835) (Fig. 1d).

Linear regression analysis indicated a significant correlation between qPCR and ddPCR values. The R-square was 0.900 for miR-197-3p (Fig.2).

Correlation studies between miRNA expression and clinicopathological characteristics for WEA

Clinicopathologic characteristics, anamnestic, occupational and non-occupational information were collected for the WEA cohort (Tables 1 and 2) and studied to look for any possible correlation with miR-197-3p expression. Spearman correlation coefficients were calculated between the miRNA quantity and the evaluated independent variables. An inverse correlation was observed between miR-197-3p and cumulative asbestos exposure in the WEA cohort (Table 1). This cohort was divided into three subgroups according to the level of cumulative asbestos exposure, as follows: range 1 (0-8 asbestos fibers/cm³ of air, ff/cc), range 2: 8-55 ff/cc, range 3: for higher than 55 ff/cc exposure. Absolute miR-197-3p quantification by RT-qPCR in WEA sera detected a mean of 352.7 copies/ul in range 1; 465.9 copies/ul in range 2 and 245.9 copies/ul, in range 3, but the differences were not statistically significant ($p>0.05$) (Fig. 3a). These data were confirmed and extended using ddPCR analysis, which showed two significant differences. Indeed, ddPCR revealed the following quantity of miR-197-3p in WEA sera: a mean of 667.8 copies/ul in range 1; 712.3 copies/ul in range 2 and 326.2 copies/ul in range 3. The quantity of miR-197-3p in WEA sera in range 3, revealed by ddPCR, is statistically different from range 1 ($p=0.0297^*$; showing up-regulation by 2.0 times) and from range 2 ($p=0.0239^*$; showing up-regulation by 2.1 times) (Fig. 3b).

No other statistically significant correlation was found between miR-197-3p levels and the other clinicopathologic characteristics taken into consideration, such as (i) asbestos exposure duration, (ii) years since last previous asbestos exposure, (iii) tobacco exposure, (iv) asbestosis or other asbestos related pathologies, (v) other diseases, unrelated to asbestos and (vi) pharmacological therapies (Table 3).

Table 3 Correlation coefficients between miRNA expression and independent variables in the WEA cohort according to Spearman. Correlation coefficients were determined according to the Spearman test. miRNA levels were expressed as copies/μl of analyzed cDNA. Correlations with $p < 0.05(*)$ were considered statistically significant.

		miR-197-3p	
		ddPCR	RT-qPCR
Age		-0.223	-0.112
Gender		0.215	0.208
Smoking status		0.154	0.127
P/Y		-0.105	-0.077
Asbestos exposure	Cumulative exposure	-0.389*	-0.197
	Years of exposure	-0.003	0.002
	Years since last previous exposure	-0.140	-0.085
	Asbestos related pathologies	-0.028	0.047
Other diseases, unrelated to asbestos	Musculoskeletal	0.114	0.131
	Cardiovascular	-0.056	-0.101
	Gastrointestinal	-0.091	-0.065
	Endocrine and diabetes	-0.256	-0.120
	Respiratory	-0.091	-0.049
	Neurological	0.129	0.099
	Genitourinary	-0.126	-0.124
	Neoplastic	0.022	0.121
	Therapy	0.110	0.051

DISCUSSION

Many studies have indicated that miRNAs, which are detectable in sera/cells from subjects who have previously been exposed to toxic agents, or are affected by inflammatory and/or other disorders, could be considered promising biomarkers^{13,17,18}. Identifying such sensitive and specific markers for asbestos exposure in WEA appears to be of paramount importance for this class of workers, who are at risk of developing MPM. In this study, circulating miR-197-3p was investigated as a potential biomarker for asbestos exposure. MiR-197-3p, whose gene maps in chromosome 1p13.3, has been reported as being involved in cellular processes, such as cell proliferation, apoptosis, differentiation, metastasis and drug resistance¹⁹. Significant miR-197-3p dysregulation has been detected in sera/cells in human diseases including tumors^{20–23}. In addition, miR-197-3p has been reported as playing a pivotal role as an oncogene or tumor suppressor gene by targeting key pathways²⁴. Some investigations have revealed that a miR-197-mediated CKS1B/STAT3 axis exerts a role in tumor progression, which is regulated by different genes, such as Bcl-2, c-Myc, and cyclin D1²⁵.

In this study circulating miR-197-3p was investigated using two PCR techniques. Digital droplet PCR (ddPCR) is an improvement on the conventional PCR technique, as it allows for a more sensitive and accurate quantification of target nucleic acids^{26–33}. DdPCR is considered as being able to overcome problems relating to potential discrepancies in PCR analyses. In particular, when compared to the traditional qPCR, the ddPCR technique exhibits some advantages: (i) ddPCR performs absolute quantification based on the principles of sample partitioning and Poisson statistics, thus overcoming normalization and calibrator issues^{15,26,33}; (ii) it is relatively insensitive to potential PCR inhibitors^{34–36}; (iii) it has shown increased precision and sensitivity in detecting low target copies^{29,37,38}; (iv) it provides analysis results directly expressed as the number of copies of target per microliter of reaction^{15,32,39}. Specifically, in this study, the classic method, i.e., RT-qPCR, was combined with the more innovative ddPCR, in order to improve results. Specifically, in this study, the classic method, i.e., RT-qPCR, was combined with the more innovative ddPCR, in order to improve the results. Our data

indicates that miR-197-3p is significantly down-regulated in WEA vs. HS employing both techniques. RT-qPCR and ddPCR highlight that miR-197-3p levels are significantly lower in WEA compared to HS sera by 2.6 times and 2.5 times, respectively. Statistical analyses confirm that comparative data, i.e., WEA vs. HS, are significant. Moreover, the two ROC analyses show that this miR-197-3p is a good parameter for distinguishing the WEA cohort from the HS group. A significant correlation between qPCR and ddPCR values, as indicated by linear regression analysis, confers higher robustness to our results.

It is well known that asbestos fibers can induce alterations in the immune system, while being involved in the inflammatory process⁴⁰⁻⁴². Different studies have reported miR-197-3p as being significantly down-regulated in inflammatory conditions⁴³. In addition, cross-talk between miR-197-3p and different interleukin signaling has also been identified^{23,43}. Specifically, IL22R1 and IL-17A subunits, which are involved in inflammatory responses, are among the validated target genes for miR-197-3p^{43 44}. Furthermore, the demonstration that miR-197-3p directly binds to one of the key molecules in the inflammatory pathways, which is the interleukin-1beta (IL-1 β) receptor, type I (IL1R1) gene, explain why miR-197-3p shows an anti-inflammatory effect in different cell types⁴⁵. Taken together, these data indicate miR-197-3p is a significant marker/parameter to be considered in the chronic inflammation processes taking place in asbestos-exposed workers.

In addition, MiR-197-3p levels showed an inverse correlation with the cumulative asbestos exposure in the WEA cohort. This result suggests that miR-197-3p could be a potential marker of the cumulative level of exposure for the oncogenic mineral in WEA. WEA exposed to a lower number of asbestos fibers exhibit higher miR-197-3p serum levels, whereas WEA exposed to higher concentrations of asbestos showed lower amounts of miR-197-3p in their serum. This result was confirmed when both PCR techniques were employed. Interestingly, data obtained using the more analytical ddPCR indicate that differing quantities of miR-197-3p in WEA sera with low exposure compared to WEA with high asbestos exposure are statistically significant. Other clinicopathologic

characteristics analyzed herein did not show statistically significant correlation with miR-197-3p levels.

Overall, the investigated circulating miR-197-3p was found to be down-regulated in WEA vs. HS and its concentration decreases with an increase in the amount of inhaled asbestos fibers. From this result it may be inferred that inhaled asbestos fibers affect the down-expression of circulating miR-197-3p. Further investigations are needed to elucidate the role of miR-197-3p in WEA and the effect of its down-regulation induced by asbestos. More information on this field could be obtained by the identification/validation of miR-197-3p target genes.

Our study indicates that miR-197-3p is a new biomarker for asbestos exposure and asbestos cumulative levels in WEA. It is worth noting that there are still a worrying lack of reliable markers for asbestos-fiber exposure. Consequently, miR-197-3p may represent a new parameter for analysis in WEA sera. Liquid biopsies can be obtained from individuals with low invasive methods. Moreover, this miRNA appears to be a quantifiable, specific and sensitive biomarker. Complimenting current follow-up analyses with a minimally invasive screening test for circulating miRNA-197-3p as a biomarker could add further relevant information on WEA subjects who are at a high-risk of developing malignant pleural mesothelioma. Thus, specific and sensitive biomarkers, such as miR 197-3p, can be employed, alongside spirometry and X-ray chest analysis, during follow-up for WEA subjects.

Institutional Review Board Statement

The study was conducted according to the guidelines of the Declaration of Helsinki. The Ethics Committee of Ferrara approved the study (Authorization number 160986).

All subjects gave their written informed consent.

Data availability

The datasets supporting the results are available from the corresponding author on reasonable request.

Conflict of interest

The following authors: IB, FF, ET, GDM, EM, MRI, CM, PB, MS, RL, RG, FM and MT declare that data from this study has been employed, in part, for the Italian patent application number RBI17430-IT.

References

1. Aust, A. E., Cook, P. M. & Dodson, R. F. Morphological and Chemical Mechanisms of Elongated Mineral Particle Toxicities. *J. Toxicol. Environ. Heal. Part B* **14**, 40–75 (2011).
2. Nelson, H. H. & Kelsey, K. T. The molecular epidemiology of asbestos and tobacco in lung cancer. *Oncogene* **21**, 7284–7288 (2002).
3. LaDou, J. *et al.* The Case for a Global Ban on Asbestos. *Environ. Health Perspect.* **118**, 897–901 (2010).
4. Huang, S. X. L., Jaurand, M.-C., Kamp, D. W., Whysner, J. & Hei, T. K. Role of Mutagenicity in Asbestos Fiber-Induced Carcinogenicity and Other Diseases. *J. Toxicol. Environ. Heal. Part B* **14**, 179–245 (2011).
5. Driscoll, T. *et al.* Global and regional burden of disease and injury in 2016 arising from occupational exposures: A systematic analysis for the Global Burden of Disease Study 2016. *Occupational and Environmental Medicine* **77**, 133–141 (2020).
6. Benedetti, S., Nuvoli, B., Catalani, S. & Galati, R. Reactive oxygen species a double-edged sword for mesothelioma. *Oncotarget* **6**, 16848–16865 (2015).
7. Kane, A. B. Oncogenes and Tumor Suppressor Genes in the Carcinogenicity of Fibers and Particles. *Inhal. Toxicol.* **12**, 133–140 (2000).
8. Rossini, M. *et al.* New perspectives on diagnosis and therapy of malignant pleural mesothelioma. *Frontiers in Oncology* **8**, 91 (2018).
9. Marsh, G. M., Riordan, A. S., Keeton, K. A. & Benson, S. M. Non-occupational exposure to asbestos and risk of pleural mesothelioma: review and meta-analysis. *Occup. Environ. Med.*

74, 838–846 (2017).

10. Asbestos-related disease: screening and diagnosis - PubMed. Available at: <https://pubmed.ncbi.nlm.nih.gov/22870590/>. (Accessed: 20th May 2021)
11. Eypert-Blaison, C., Romero-Hariot, A., Clerc, F. & Vincent, R. Assessment of occupational exposure to asbestos fibers: Contribution of analytical transmission electron microscopy analysis and comparison with phase-contrast microscopy. *J. Occup. Environ. Hyg.* **15**, 263–274 (2018).
12. Di Leva, G., Garofalo, M. & Croce, C. M. MicroRNAs in cancer. *Annu. Rev. Pathol. Mech. Dis.* **9**, 287–314 (2014).
13. Hayes, J., Peruzzi, P. P. & Lawler, S. MicroRNAs in cancer: Biomarkers, functions and therapy. *Trends in Molecular Medicine* **20**, 460–469 (2014).
14. Bononi, I. *et al.* Circulating microRNAs found dysregulated in ex-exposed asbestos workers and pleural mesothelioma patients as potential new biomarkers. *Oncotarget* **7**, 82700–82711 (2016).
15. Campomenosi, P. *et al.* A comparison between quantitative PCR and droplet digital PCR technologies for circulating microRNA quantification in human lung cancer. *BMC Biotechnol.* **16**, (2016).
16. Rotondo, J. C., Mazzoni, E., Bononi, I., Tognon, M. & Martini, F. Association Between Simian Virus 40 and Human Tumors. *Front. Oncol.* **9**, (2019).
17. Fabbri, M. *et al.* MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response. *Proc. Natl. Acad. Sci.* **109**, E2110–E2116 (2012).
18. Vrijens, K., Bollati, V. & Nawrot, T. S. MicroRNAs as potential signatures of environmental exposure or effect: A systematic review. *Environmental Health Perspectives* **123**, 399–411 (2015).
19. Huang, J. T., Wang, J., Srivastava, V., Sen, S. & Liu, S. M. MicroRNA machinery genes as novel biomarkers for cancer. *Frontiers in Oncology* **4 MAY**, (2014).

20. Remon, J. *et al.* miRNA-197 and miRNA-184 are associated with brain metastasis in EGFR-mutant lung cancers. *Clin. Transl. Oncol.* **18**, 153–159 (2016).
21. Shaker, O., Maher, M., Nassar, Y., Morcos, G. & Gad, Z. Role of microRNAs -29b-2, -155, -197 and -205 as diagnostic biomarkers in serum of breast cancer females. *Gene* **560**, 77–82 (2015).
22. Hamada, S. *et al.* miR-197 induces epithelial-mesenchymal transition in pancreatic cancer cells by targeting p120 catenin. *J. Cell. Physiol.* **228**, 1255–1263 (2013).
23. Wang, H. *et al.* Reciprocal control of miR-197 and IL-6/STAT3 pathway reveals miR-197 as potential therapeutic target for hepatocellular carcinoma. *Oncoimmunology* **4**, (2015).
24. Wang, D. dan *et al.* miR-197: A novel biomarker for cancers. *Gene* **591**, 313–319 (2016).
25. Fujita, Y. *et al.* The clinical relevance of the miR-197/CKS1B/STAT3-mediated PD-L1 network in chemoresistant non-small-cell lung cancer. *Mol. Ther.* **23**, 717–727 (2015).
26. Hindson, C. M. *et al.* Absolute quantification by droplet digital PCR versus analog real-time PCR. *Nat. Methods* **10**, 1003–1005 (2013).
27. Rotondo, J. C. *et al.* Simultaneous detection and viral DNA load quantification of different human papillomavirus types in clinical specimens by the high analytical droplet digital PCR method. *Front. Microbiol.* **11**, 1–14 (2020).
28. Miotto, E. *et al.* Quantification of circulating miRNAs by droplet digital PCR: Comparison of EvaGreen- and TaqMan-based chemistries. *Cancer Epidemiol. Biomarkers Prev.* **23**, 2638–2642 (2014).
29. Mazzoni, E. *et al.* Detection of Merkel Cell Polyomavirus DNA in Serum Samples of Healthy Blood Donors. *Front. Oncol.* **7**, (2017).
30. Tagliapietra, A. *et al.* Footprints of BK and JC polyomaviruses in specimens from females affected by spontaneous abortion. *Hum. Reprod.* **34**, 433–440 (2018).
31. Tagliapietra, A. *et al.* Droplet-digital PCR assay to detect Merkel cell polyomavirus sequences in chorionic villi from spontaneous abortion affected females. *J. Cell. Physiol.*

- 235**, 1888–1894 (2019).
32. Torreggiani, E. *et al.* Protocol for the long-term culture of human primary keratinocytes from the normal colorectal mucosa. *J. Cell. Physiol.* **234**, 9895–9905 (2019).
 33. Ferracin, M. *et al.* Absolute quantification of cell-free microRNAs in cancer patients. *Oncotarget* **6**, 14545–14555 (2015).
 34. Rački, N., Dreo, T., Gutierrez-Aguirre, I., Blejec, A. & Ravnkar, M. Reverse transcriptase droplet digital PCR shows high resilience to PCR inhibitors from plant, soil and water samples. *Plant Methods* **10**, (2014).
 35. Doi, H. *et al.* Droplet digital polymerase chain reaction (PCR) outperforms real-time PCR in the detection of environmental DNA from an invasive fish species. *Environ. Sci. Technol.* **49**, 5601–5608 (2015).
 36. Huggett, J. F. *et al.* Differential susceptibility of PCR reactions to inhibitors: An important and unrecognised phenomenon. *BMC Res. Notes* **1**, (2008).
 37. Zhao, S. *et al.* Sensitive detection of Porcine circovirus-2 by droplet digital polymerase chain reaction. *J. Vet. Diagnostic Investig.* **27**, 784–788 (2015).
 38. Brunetto, G. S. *et al.* Digital droplet PCR (ddPCR) for the precise quantification of human T-lymphotropic virus 1 proviral loads in peripheral blood and cerebrospinal fluid of HAM/TSP patients and identification of viral mutations. *J. Neurovirol.* **20**, 341–351 (2014).
 39. Hindson, B. J. *et al.* High-Throughput Droplet Digital PCR System for Absolute Quantitation of DNA Copy Number. *Anal. Chem.* **83**, 8604–8610 (2011).
 40. Corti, A. *et al.* Induction of Gamma-Glutamyltransferase Activity and Consequent Pro-oxidant Reactions in Human Macrophages Exposed to Crocidolite Asbestos. *Toxicol. Sci.* **177**, 476–482 (2019).
 41. Nishimura, Y. *et al.* Altered functions of alveolar macrophages and NK cells involved in asbestos-related diseases. *Environ. Health Prev. Med.* **18**, 198–204 (2013).
 42. Matsuzaki, H. Exploration of Biomarkers for Asbestos Exposure and Occurrence of

Malignant Mesothelioma Based on the Immunological Effects of Asbestos. *J. Data Mining Genomics Proteomics* **04**, 1–5 (2013).

43. Lerman, G., Sharon, M., Leibowitz-Amit, R., Sidi, Y. & Avni, D. The crosstalk between IL-22 signaling and miR-197 in human keratinocytes. *PLoS One* **9**, (2014).
44. Masalha, M., Sidi, Y. & Avni, D. The contribution of feedback loops between miRNAs, cytokines and growth factors to the pathogenesis of psoriasis. *Experimental Dermatology* **27**, 603–610 (2018).
45. Akkaya-Ulum, Y. Z. *et al.* Familial Mediterranean fever-related miR-197-3p targets IL1R1 gene and modulates inflammation in monocytes and synovial fibroblasts. *Sci. Rep.* **11**, (2021).

Acknowledgements

We thank Ms. Georgia Emma Gili for revising the English text of the manuscript.

Author Contributions

Study design by M.T., F.M., F.F. and I.B. Resources by M.S., P.B., R.L., R.G., F.G. and G.G. Data collection by F.F., I.B. and G.D.M. Data analysis and interpretation by F.F., I.B., E.T. and E.M. Manuscript preparation by F.F., I.B., G.D.M. and E.T. Supervision and project administration by F.M. and M.T.. All authors have read and agreed to the submitted version of the manuscript.

Funding

This work was supported by Fondazione AIRC (grant IG 21617), Fondazione Buzzi Unicem Onlus (grant biannual project CFR) and University of Ferrara (FAR projects 2019)

Competing interests

The authors declare that part of the data were used for a national patent application.

Additional information

Correspondence and requests for materials should be addressed to F.M. and M.T.

Figures' legends

Figure 1. miR-197-3p quantification. **a** miR-197-3p quantification in sera from WEA and HS cohorts using RT-qPCR. **b** ROC curve to quantify RT-qPCR accuracy. **c** miR-197-3p quantification in sera from WEA and HS cohorts using dd-PCR. **d** ROC curve to quantify dd-PCR accuracy.

Figure 2. Linear regression. Linear regression analysis for the correlation between qPCR and ddPCR values.

Figure 3. Correlation between miR-197-3p and cumulative asbestos exposure. Correlation between miR-197-3p sera expression and cumulative asbestos exposure in WEA cohort highlighted by RT-qPCR **a** and by dd-PCR **b**.